CBIZ, Inc. (NYSE: CBZ), a leading national professional services advisor, announced the release of its 2025 State of ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

Despite its popularity, Ozempic often leads to temporary weight loss, carries serious side effects, and most users regain ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

A former head of the US Food and Drug Administration cut his body fat in half using GLP-1 drugs. In his book, he compares the ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Ozempic, a prescription drug typically used to manage type 2 diabetes, is fast turning into an answer for quick weight loss ...

Ozempic users find that it not only promotes weight loss but also helps lower the risk of heart disease, high blood pressure, type 2 diabetes, and other obesity-related conditions. Science tells ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that ...